FAQs
The studies you presented are representing small patient numbers - are they really representative?
These studies had specific objectives. The endpoints for PRECISION I & II were safety, efficacy and pharmacokinetics. These endpoints were met.
We are now recruiting patients into PRECISION V which is a phase III randomised clinical trial comparing the DC Bead with conventional TACE. This is the biggest ever clinical trial of its type.
The data from PRECISION I was positive - the tumour response rate was 87% at six months at the highest 150mg dose - we would ask clinicians to review their practice in order to be able to offer patients the benefits of DC Bead now.
In this section
Disclaimer
The products may not be available for sale, may not be registered, approved or cleared for use as claimed, in all countries where Biocompatibles is represented.